APO Research
Talk to an analyst

APO RESEARCH · REPORT

Biologic Medications for Psoriasis

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Biologic Medications for Psoriasis Market Outlook and Growth Opportunities 2026

27 December 2025206 pages

Choose your research edition.

Industry ResearchBiologic Medications for Psoriasis Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Biologic Medications for Psoriasis Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Biologic Medications for Psoriasis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biologic Medications for Psoriasis Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal Biologic Medications for Psoriasis Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Biologic Medications for Psoriasis market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Biologic Medications for Psoriasis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Biologic Medications for Psoriasis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Biologic Medications for Psoriasis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Biologic Medications for Psoriasis market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Biologic Medications for Psoriasis market include AbbVie Biotechnology, Amgen, Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly, Janssen Biotech, Kyowa Kirin, LEO Pharma and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Biologic Medications for Psoriasis market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Biologic Medications for Psoriasis and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Biologic Medications for Psoriasis sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Biologic Medications for Psoriasis market size, projected growth trends, production technologies, key applications, and end-use industries.

Biologic Medications for Psoriasis Segment by Company

AbbVie Biotechnology

Amgen

Boehringer Ingelheim Pharmaceuticals

Bristol-Myers Squibb

Eli Lilly

Janssen Biotech

Kyowa Kirin

LEO Pharma

Novartis

Ortho Dermatologics

Pfizer

Samsung Bioepis

Tiefenbacher Pharmaceuticals

UCB

Dalian Yawei Pharmaceutical

Hanwha Chemical

China Medical System

Qilu Pharmaceutical

Biologic Medications for Psoriasis Segment by Type

Interleukin Inhibitors

Tyrosine Kinase Inhibitors

Phosphodiesterase Inhibitors

TNF-α Inhibitors

Other

Biologic Medications for Psoriasis Segment by Application

Retail Pharmacies

Hospital and Clinic

Other

Biologic Medications for Psoriasis Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Biologic Medications for Psoriasis status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Biologic Medications for Psoriasis market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Biologic Medications for Psoriasis significant trends, drivers, influence factors in global and regions.

6. To analyze Biologic Medications for Psoriasis competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologic Medications for Psoriasis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biologic Medications for Psoriasis and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologic Medications for Psoriasis.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Biologic Medications for Psoriasis market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Biologic Medications for Psoriasis industry.

Chapter 3: Detailed analysis of Biologic Medications for Psoriasis manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Biologic Medications for Psoriasis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Biologic Medications for Psoriasis in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Biologic Medications for Psoriasis Industry Trends Table 2. Biologic Medications for Psoriasis Industry Drivers Table 3. Biologic Medications for Psoriasis Industry Opportunities and Challenges Table 4. Biologic Medications for Psoriasis Industry Restraints Table 5. Global Biologic Medications for Psoriasis Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Biologic Medications for Psoriasis Revenue Share by Company (2021-2026) Table 7. Global Biologic Medications for Psoriasis Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Biologic Medications for Psoriasis Sales Volume Share by Company (2021-2026) Table 9. Global Biologic Medications for Psoriasis Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Biologic Medications for Psoriasis Company Ranking, (2024-2026) & (USD Million) Table 11. Global Biologic Medications for Psoriasis Key Company Manufacturing Base & Headquarters Table 12. Global Biologic Medications for Psoriasis Company, Product Type & Application Table 13. Global Biologic Medications for Psoriasis Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Biologic Medications for Psoriasis by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Interleukin Inhibitors Table 18. Significant Companies of Tyrosine Kinase Inhibitors Table 19. Significant Companies of Phosphodiesterase Inhibitors Table 20. Significant Companies of TNF-α Inhibitors Table 21. Significant Companies of Other Table 22. Global Biologic Medications for Psoriasis Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Biologic Medications for Psoriasis Sales Volume by Type (2021-2026) & (K Units) Table 24. Global Biologic Medications for Psoriasis Sales Volume by Type (2027-2032) & (K Units) Table 25. Global Biologic Medications for Psoriasis Sales Volume Share by Type (2021-2026) Table 26. Global Biologic Medications for Psoriasis Sales Volume Share by Type (2027-2032) Table 27. Global Biologic Medications for Psoriasis Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Biologic Medications for Psoriasis Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Biologic Medications for Psoriasis Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Biologic Medications for Psoriasis Sales Value Share by Type (2021-2026) Table 31. Global Biologic Medications for Psoriasis Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Retail Pharmacies Table 33. Significant Companies of Hospital and Clinic Table 34. Significant Companies of Other Table 35. Global Biologic Medications for Psoriasis Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Biologic Medications for Psoriasis Sales Volume by Application (2021-2026) & (K Units) Table 37. Global Biologic Medications for Psoriasis Sales Volume by Application (2027-2032) & (K Units) Table 38. Global Biologic Medications for Psoriasis Sales Volume Share by Application (2021-2026) Table 39. Global Biologic Medications for Psoriasis Sales Volume Share by Application (2027-2032) Table 40. Global Biologic Medications for Psoriasis Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Biologic Medications for Psoriasis Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Biologic Medications for Psoriasis Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Biologic Medications for Psoriasis Sales Value Share by Application (2021-2026) Table 44. Global Biologic Medications for Psoriasis Sales Value Share by Application (2027-2032) Table 45. Global Biologic Medications for Psoriasis Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Biologic Medications for Psoriasis Sales by Region (2021-2026) & (K Units) Table 47. Global Biologic Medications for Psoriasis Sales Market Share by Region (2021-2026) Table 48. Global Biologic Medications for Psoriasis Sales by Region (2027-2032) & (K Units) Table 49. Global Biologic Medications for Psoriasis Sales Market Share by Region (2027-2032) Table 50. Global Biologic Medications for Psoriasis Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Biologic Medications for Psoriasis Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Biologic Medications for Psoriasis Sales Value Share by Region (2021-2026) Table 53. Global Biologic Medications for Psoriasis Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Biologic Medications for Psoriasis Sales Value Share by Region (2027-2032) Table 55. Global Biologic Medications for Psoriasis Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global Biologic Medications for Psoriasis Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global Biologic Medications for Psoriasis Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global Biologic Medications for Psoriasis Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Biologic Medications for Psoriasis Sales by Country (2021-2026) & (K Units) Table 60. Global Biologic Medications for Psoriasis Sales Market Share by Country (2021-2026) Table 61. Global Biologic Medications for Psoriasis Sales by Country (2027-2032) & (K Units) Table 62. Global Biologic Medications for Psoriasis Sales Market Share by Country (2027-2032) Table 63. Global Biologic Medications for Psoriasis Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Biologic Medications for Psoriasis Sales Value Market Share by Country (2021-2026) Table 65. Global Biologic Medications for Psoriasis Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Biologic Medications for Psoriasis Sales Value Market Share by Country (2027-2032) Table 67. AbbVie Biotechnology Company Information Table 68. AbbVie Biotechnology Business Overview Table 69. AbbVie Biotechnology Biologic Medications for Psoriasis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. AbbVie Biotechnology Biologic Medications for Psoriasis Product Portfolio Table 71. AbbVie Biotechnology Recent Development Table 72. Amgen Company Information Table 73. Amgen Business Overview Table 74. Amgen Biologic Medications for Psoriasis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Amgen Biologic Medications for Psoriasis Product Portfolio Table 76. Amgen Recent Development Table 77. Boehringer Ingelheim Pharmaceuticals Company Information Table 78. Boehringer Ingelheim Pharmaceuticals Business Overview Table 79. Boehringer Ingelheim Pharmaceuticals Biologic Medications for Psoriasis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Boehringer Ingelheim Pharmaceuticals Biologic Medications for Psoriasis Product Portfolio Table 81. Boehringer Ingelheim Pharmaceuticals Recent Development Table 82. Bristol-Myers Squibb Company Information Table 83. Bristol-Myers Squibb Business Overview Table 84. Bristol-Myers Squibb Biologic Medications for Psoriasis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Bristol-Myers Squibb Biologic Medications for Psoriasis Product Portfolio Table 86. Bristol-Myers Squibb Recent Development Table 87. Eli Lilly Company Information Table 88. Eli Lilly Business Overview Table 89. Eli Lilly Biologic Medications for Psoriasis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Eli Lilly Biologic Medications for Psoriasis Product Portfolio Table 91. Eli Lilly Recent Development Table 92. Janssen Biotech Company Information Table 93. Janssen Biotech Business Overview Table 94. Janssen Biotech Biologic Medications for Psoriasis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Janssen Biotech Biologic Medications for Psoriasis Product Portfolio Table 96. Janssen Biotech Recent Development Table 97. Kyowa Kirin Company Information Table 98. Kyowa Kirin Business Overview Table 99. Kyowa Kirin Biologic Medications for Psoriasis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Kyowa Kirin Biologic Medications for Psoriasis Product Portfolio Table 101. Kyowa Kirin Recent Development Table 102. LEO Pharma Company Information Table 103. LEO Pharma Business Overview Table 104. LEO Pharma Biologic Medications for Psoriasis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. LEO Pharma Biologic Medications for Psoriasis Product Portfolio Table 106. LEO Pharma Recent Development Table 107. Novartis Company Information Table 108. Novartis Business Overview Table 109. Novartis Biologic Medications for Psoriasis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Novartis Biologic Medications for Psoriasis Product Portfolio Table 111. Novartis Recent Development Table 112. Ortho Dermatologics Company Information Table 113. Ortho Dermatologics Business Overview Table 114. Ortho Dermatologics Biologic Medications for Psoriasis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Ortho Dermatologics Biologic Medications for Psoriasis Product Portfolio Table 116. Ortho Dermatologics Recent Development Table 117. Pfizer Company Information Table 118. Pfizer Business Overview Table 119. Pfizer Biologic Medications for Psoriasis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Pfizer Biologic Medications for Psoriasis Product Portfolio Table 121. Pfizer Recent Development Table 122. Samsung Bioepis Company Information Table 123. Samsung Bioepis Business Overview Table 124. Samsung Bioepis Biologic Medications for Psoriasis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Samsung Bioepis Biologic Medications for Psoriasis Product Portfolio Table 126. Samsung Bioepis Recent Development Table 127. Tiefenbacher Pharmaceuticals Company Information Table 128. Tiefenbacher Pharmaceuticals Business Overview Table 129. Tiefenbacher Pharmaceuticals Biologic Medications for Psoriasis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Tiefenbacher Pharmaceuticals Biologic Medications for Psoriasis Product Portfolio Table 131. Tiefenbacher Pharmaceuticals Recent Development Table 132. UCB Company Information Table 133. UCB Business Overview Table 134. UCB Biologic Medications for Psoriasis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. UCB Biologic Medications for Psoriasis Product Portfolio Table 136. UCB Recent Development Table 137. Dalian Yawei Pharmaceutical Company Information Table 138. Dalian Yawei Pharmaceutical Business Overview Table 139. Dalian Yawei Pharmaceutical Biologic Medications for Psoriasis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Dalian Yawei Pharmaceutical Biologic Medications for Psoriasis Product Portfolio Table 141. Dalian Yawei Pharmaceutical Recent Development Table 142. Hanwha Chemical Company Information Table 143. Hanwha Chemical Business Overview Table 144. Hanwha Chemical Biologic Medications for Psoriasis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 145. Hanwha Chemical Biologic Medications for Psoriasis Product Portfolio Table 146. Hanwha Chemical Recent Development Table 147. China Medical System Company Information Table 148. China Medical System Business Overview Table 149. China Medical System Biologic Medications for Psoriasis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 150. China Medical System Biologic Medications for Psoriasis Product Portfolio Table 151. China Medical System Recent Development Table 152. Qilu Pharmaceutical Company Information Table 153. Qilu Pharmaceutical Business Overview Table 154. Qilu Pharmaceutical Biologic Medications for Psoriasis Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 155. Qilu Pharmaceutical Biologic Medications for Psoriasis Product Portfolio Table 156. Qilu Pharmaceutical Recent Development Table 157. Key Raw Materials Table 158. Raw Materials Key Suppliers Table 159. Biologic Medications for Psoriasis Distributors List Table 160. Biologic Medications for Psoriasis Customers List Table 161. Research Programs/Design for This Report Table 162. Authors List of This Report Table 163. Secondary Sources Table 164. Primary Sources List of Figures Figure 1. Biologic Medications for Psoriasis Product Image Figure 2. Global Biologic Medications for Psoriasis Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biologic Medications for Psoriasis Sales Value (2021-2032) & (US$ Million) Figure 4. Global Biologic Medications for Psoriasis Sales (2021-2032) & (K Units) Figure 5. Global Biologic Medications for Psoriasis Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Biologic Medications for Psoriasis Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Interleukin Inhibitors Image Figure 10. Tyrosine Kinase Inhibitors Image Figure 11. Phosphodiesterase Inhibitors Image Figure 12. TNF-α Inhibitors Image Figure 13. Other Image Figure 14. Global Biologic Medications for Psoriasis Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Biologic Medications for Psoriasis Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Biologic Medications for Psoriasis Sales Volume Share by Type (2021-2032) Figure 17. Global Biologic Medications for Psoriasis Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Biologic Medications for Psoriasis Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Biologic Medications for Psoriasis Sales Value Share by Type (2021-2032) Figure 20. Retail Pharmacies Image Figure 21. Hospital and Clinic Image Figure 22. Other Image Figure 23. Global Biologic Medications for Psoriasis Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Biologic Medications for Psoriasis Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Biologic Medications for Psoriasis Sales Volume Share by Application (2021-2032) Figure 26. Global Biologic Medications for Psoriasis Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Biologic Medications for Psoriasis Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Biologic Medications for Psoriasis Sales Value Share by Application (2021-2032) Figure 29. Global Biologic Medications for Psoriasis Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global Biologic Medications for Psoriasis Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Biologic Medications for Psoriasis Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Biologic Medications for Psoriasis Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Biologic Medications for Psoriasis Sales Value (2021-2032) & (US$ Million) Figure 34. North America Biologic Medications for Psoriasis Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Biologic Medications for Psoriasis Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Biologic Medications for Psoriasis Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Biologic Medications for Psoriasis Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Biologic Medications for Psoriasis Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Biologic Medications for Psoriasis Sales Value (2021-2032) & (US$ Million) Figure 40. South America Biologic Medications for Psoriasis Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Biologic Medications for Psoriasis Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Biologic Medications for Psoriasis Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Biologic Medications for Psoriasis Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Biologic Medications for Psoriasis Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Interleukin Inhibitors
  • Tyrosine Kinase Inhibitors
  • Phosphodiesterase Inhibitors
  • TNF-α Inhibitors
  • Other
Applications
  • Retail Pharmacies
  • Hospital and Clinic
  • Other
Companies covered
  • AbbVie Biotechnology
  • Amgen
  • Boehringer Ingelheim Pharmaceuticals
  • Bristol-Myers Squibb
  • Eli Lilly
  • Janssen Biotech
  • Kyowa Kirin
  • LEO Pharma
  • Novartis
  • Ortho Dermatologics
  • Pfizer
  • Samsung Bioepis
  • Tiefenbacher Pharmaceuticals
  • UCB
  • Dalian Yawei Pharmaceutical
  • Hanwha Chemical
  • China Medical System
  • Qilu Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Biologic Medications for Psoriasis Sales Value (2021-2032)
  4. 1.2.2 Global Biologic Medications for Psoriasis Sales Volume (2021-2032)
  5. 1.2.3 Global Biologic Medications for Psoriasis Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Biologic Medications for Psoriasis Market Dynamics
  1. 2.1 Biologic Medications for Psoriasis Industry Trends
  2. 2.2 Biologic Medications for Psoriasis Industry Drivers
  3. 2.3 Biologic Medications for Psoriasis Industry Opportunities and Challenges
  4. 2.4 Biologic Medications for Psoriasis Industry Restraints
3 Biologic Medications for Psoriasis Market by Company
  1. 3.1 Global Biologic Medications for Psoriasis Company Revenue Ranking in 2025
  2. 3.2 Global Biologic Medications for Psoriasis Revenue by Company (2021-2026)
  3. 3.3 Global Biologic Medications for Psoriasis Sales Volume by Company (2021-2026)
  4. 3.4 Global Biologic Medications for Psoriasis Average Price by Company (2021-2026)
  5. 3.5 Global Biologic Medications for Psoriasis Company Ranking (2024-2026)
  6. 3.6 Global Biologic Medications for Psoriasis Company Manufacturing Base and Headquarters
  7. 3.7 Global Biologic Medications for Psoriasis Company Product Type and Application
  8. 3.8 Global Biologic Medications for Psoriasis Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Biologic Medications for Psoriasis Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Biologic Medications for Psoriasis Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Biologic Medications for Psoriasis Market by Type
  1. 4.1 Biologic Medications for Psoriasis Type Introduction
  2. 4.1.1 Interleukin Inhibitors
  3. 4.1.2 Tyrosine Kinase Inhibitors
  4. 4.1.3 Phosphodiesterase Inhibitors
  5. 4.1.4 TNF-α Inhibitors
  6. 4.1.5 Other
  7. 4.2 Global Biologic Medications for Psoriasis Sales Volume by Type
  8. 4.2.1 Global Biologic Medications for Psoriasis Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Biologic Medications for Psoriasis Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Biologic Medications for Psoriasis Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Biologic Medications for Psoriasis Sales Value by Type
  12. 4.3.1 Global Biologic Medications for Psoriasis Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Biologic Medications for Psoriasis Sales Value by Type (2021-2032)
  14. 4.3.3 Global Biologic Medications for Psoriasis Sales Value Share by Type (2021-2032)
5 Biologic Medications for Psoriasis Market by Application
  1. 5.1 Biologic Medications for Psoriasis Application Introduction
  2. 5.1.1 Retail Pharmacies
  3. 5.1.2 Hospital and Clinic
  4. 5.1.3 Other
  5. 5.2 Global Biologic Medications for Psoriasis Sales Volume by Application
  6. 5.2.1 Global Biologic Medications for Psoriasis Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Biologic Medications for Psoriasis Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Biologic Medications for Psoriasis Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Biologic Medications for Psoriasis Sales Value by Application
  10. 5.3.1 Global Biologic Medications for Psoriasis Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Biologic Medications for Psoriasis Sales Value by Application (2021-2032)
  12. 5.3.3 Global Biologic Medications for Psoriasis Sales Value Share by Application (2021-2032)
6 Biologic Medications for Psoriasis Regional Sales and Value Analysis
  1. 6.1 Global Biologic Medications for Psoriasis Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Biologic Medications for Psoriasis Sales by Region (2021-2032)
  3. 6.2.1 Global Biologic Medications for Psoriasis Sales by Region: 2021-2026
  4. 6.2.2 Global Biologic Medications for Psoriasis Sales by Region (2027-2032)
  5. 6.3 Global Biologic Medications for Psoriasis Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Biologic Medications for Psoriasis Sales Value by Region (2021-2032)
  7. 6.4.1 Global Biologic Medications for Psoriasis Sales Value by Region: 2021-2026
  8. 6.4.2 Global Biologic Medications for Psoriasis Sales Value by Region (2027-2032)
  9. 6.5 Global Biologic Medications for Psoriasis Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Biologic Medications for Psoriasis Sales Value (2021-2032)
  12. 6.6.2 North America Biologic Medications for Psoriasis Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Biologic Medications for Psoriasis Sales Value (2021-2032)
  15. 6.7.2 Europe Biologic Medications for Psoriasis Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Biologic Medications for Psoriasis Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Biologic Medications for Psoriasis Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Biologic Medications for Psoriasis Sales Value (2021-2032)
  21. 6.9.2 South America Biologic Medications for Psoriasis Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Biologic Medications for Psoriasis Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Biologic Medications for Psoriasis Sales Value Share by Country, 2025 VS 2032
7 Biologic Medications for Psoriasis Country-level Sales and Value Analysis
  1. 7.1 Global Biologic Medications for Psoriasis Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Biologic Medications for Psoriasis Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Biologic Medications for Psoriasis Sales by Country (2021-2032)
  4. 7.3.1 Global Biologic Medications for Psoriasis Sales by Country (2021-2026)
  5. 7.3.2 Global Biologic Medications for Psoriasis Sales by Country (2027-2032)
  6. 7.4 Global Biologic Medications for Psoriasis Sales Value by Country (2021-2032)
  7. 7.4.1 Global Biologic Medications for Psoriasis Sales Value by Country (2021-2026)
  8. 7.4.2 Global Biologic Medications for Psoriasis Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Biologic Medications for Psoriasis Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Biologic Medications for Psoriasis Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Biologic Medications for Psoriasis Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 AbbVie Biotechnology
  2. 8.1.1 AbbVie Biotechnology Company Information
  3. 8.1.2 AbbVie Biotechnology Business Overview
  4. 8.1.3 AbbVie Biotechnology Biologic Medications for Psoriasis Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 AbbVie Biotechnology Biologic Medications for Psoriasis Product Portfolio
  6. 8.1.5 AbbVie Biotechnology Recent Developments
  7. 8.2 Amgen
  8. 8.2.1 Amgen Company Information
  9. 8.2.2 Amgen Business Overview
  10. 8.2.3 Amgen Biologic Medications for Psoriasis Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Amgen Biologic Medications for Psoriasis Product Portfolio
  12. 8.2.5 Amgen Recent Developments
  13. 8.3 Boehringer Ingelheim Pharmaceuticals
  14. 8.3.1 Boehringer Ingelheim Pharmaceuticals Company Information
  15. 8.3.2 Boehringer Ingelheim Pharmaceuticals Business Overview
  16. 8.3.3 Boehringer Ingelheim Pharmaceuticals Biologic Medications for Psoriasis Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Boehringer Ingelheim Pharmaceuticals Biologic Medications for Psoriasis Product Portfolio
  18. 8.3.5 Boehringer Ingelheim Pharmaceuticals Recent Developments
  19. 8.4 Bristol-Myers Squibb
  20. 8.4.1 Bristol-Myers Squibb Company Information
  21. 8.4.2 Bristol-Myers Squibb Business Overview
  22. 8.4.3 Bristol-Myers Squibb Biologic Medications for Psoriasis Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Bristol-Myers Squibb Biologic Medications for Psoriasis Product Portfolio
  24. 8.4.5 Bristol-Myers Squibb Recent Developments
  25. 8.5 Eli Lilly
  26. 8.5.1 Eli Lilly Company Information
  27. 8.5.2 Eli Lilly Business Overview
  28. 8.5.3 Eli Lilly Biologic Medications for Psoriasis Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Eli Lilly Biologic Medications for Psoriasis Product Portfolio
  30. 8.5.5 Eli Lilly Recent Developments
  31. 8.6 Janssen Biotech
  32. 8.6.1 Janssen Biotech Company Information
  33. 8.6.2 Janssen Biotech Business Overview
  34. 8.6.3 Janssen Biotech Biologic Medications for Psoriasis Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Janssen Biotech Biologic Medications for Psoriasis Product Portfolio
  36. 8.6.5 Janssen Biotech Recent Developments
  37. 8.7 Kyowa Kirin
  38. 8.7.1 Kyowa Kirin Company Information
  39. 8.7.2 Kyowa Kirin Business Overview
  40. 8.7.3 Kyowa Kirin Biologic Medications for Psoriasis Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Kyowa Kirin Biologic Medications for Psoriasis Product Portfolio
  42. 8.7.5 Kyowa Kirin Recent Developments
  43. 8.8 LEO Pharma
  44. 8.8.1 LEO Pharma Company Information
  45. 8.8.2 LEO Pharma Business Overview
  46. 8.8.3 LEO Pharma Biologic Medications for Psoriasis Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 LEO Pharma Biologic Medications for Psoriasis Product Portfolio
  48. 8.8.5 LEO Pharma Recent Developments
  49. 8.9 Novartis
  50. 8.9.1 Novartis Company Information
  51. 8.9.2 Novartis Business Overview
  52. 8.9.3 Novartis Biologic Medications for Psoriasis Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Novartis Biologic Medications for Psoriasis Product Portfolio
  54. 8.9.5 Novartis Recent Developments
  55. 8.10 Ortho Dermatologics
  56. 8.10.1 Ortho Dermatologics Company Information
  57. 8.10.2 Ortho Dermatologics Business Overview
  58. 8.10.3 Ortho Dermatologics Biologic Medications for Psoriasis Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Ortho Dermatologics Biologic Medications for Psoriasis Product Portfolio
  60. 8.10.5 Ortho Dermatologics Recent Developments
  61. 8.11 Pfizer
  62. 8.11.1 Pfizer Company Information
  63. 8.11.2 Pfizer Business Overview
  64. 8.11.3 Pfizer Biologic Medications for Psoriasis Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Pfizer Biologic Medications for Psoriasis Product Portfolio
  66. 8.11.5 Pfizer Recent Developments
  67. 8.12 Samsung Bioepis
  68. 8.12.1 Samsung Bioepis Company Information
  69. 8.12.2 Samsung Bioepis Business Overview
  70. 8.12.3 Samsung Bioepis Biologic Medications for Psoriasis Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Samsung Bioepis Biologic Medications for Psoriasis Product Portfolio
  72. 8.12.5 Samsung Bioepis Recent Developments
  73. 8.13 Tiefenbacher Pharmaceuticals
  74. 8.13.1 Tiefenbacher Pharmaceuticals Company Information
  75. 8.13.2 Tiefenbacher Pharmaceuticals Business Overview
  76. 8.13.3 Tiefenbacher Pharmaceuticals Biologic Medications for Psoriasis Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Tiefenbacher Pharmaceuticals Biologic Medications for Psoriasis Product Portfolio
  78. 8.13.5 Tiefenbacher Pharmaceuticals Recent Developments
  79. 8.14 UCB
  80. 8.14.1 UCB Company Information
  81. 8.14.2 UCB Business Overview
  82. 8.14.3 UCB Biologic Medications for Psoriasis Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 UCB Biologic Medications for Psoriasis Product Portfolio
  84. 8.14.5 UCB Recent Developments
  85. 8.15 Dalian Yawei Pharmaceutical
  86. 8.15.1 Dalian Yawei Pharmaceutical Company Information
  87. 8.15.2 Dalian Yawei Pharmaceutical Business Overview
  88. 8.15.3 Dalian Yawei Pharmaceutical Biologic Medications for Psoriasis Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Dalian Yawei Pharmaceutical Biologic Medications for Psoriasis Product Portfolio
  90. 8.15.5 Dalian Yawei Pharmaceutical Recent Developments
  91. 8.16 Hanwha Chemical
  92. 8.16.1 Hanwha Chemical Company Information
  93. 8.16.2 Hanwha Chemical Business Overview
  94. 8.16.3 Hanwha Chemical Biologic Medications for Psoriasis Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Hanwha Chemical Biologic Medications for Psoriasis Product Portfolio
  96. 8.16.5 Hanwha Chemical Recent Developments
  97. 8.17 China Medical System
  98. 8.17.1 China Medical System Company Information
  99. 8.17.2 China Medical System Business Overview
  100. 8.17.3 China Medical System Biologic Medications for Psoriasis Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 China Medical System Biologic Medications for Psoriasis Product Portfolio
  102. 8.17.5 China Medical System Recent Developments
  103. 8.18 Qilu Pharmaceutical
  104. 8.18.1 Qilu Pharmaceutical Company Information
  105. 8.18.2 Qilu Pharmaceutical Business Overview
  106. 8.18.3 Qilu Pharmaceutical Biologic Medications for Psoriasis Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Qilu Pharmaceutical Biologic Medications for Psoriasis Product Portfolio
  108. 8.18.5 Qilu Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Biologic Medications for Psoriasis Value Chain Analysis
  2. 9.1.1 Biologic Medications for Psoriasis Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Biologic Medications for Psoriasis Sales Mode & Process
  6. 9.2 Biologic Medications for Psoriasis Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Biologic Medications for Psoriasis Distributors
  9. 9.2.3 Biologic Medications for Psoriasis Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst